Patient is not a candidate for stem cell transplant due to advanced age or co-morbidities; or the enrollee does not have donor available; or the enrollee declines stem cell transplant due to personal belief; or stem cell transplant is not standard of care based on the risk category of disease
Must not have received any prior stem cell transplant
Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements
Prior allogeneic stem cell transplant
Stem cell transplant (autologous or allogeneic) within  days of study treatment start
Prior peripheral stem cell transplant within  weeks of randomization
Allogeneic stem cell transplant within the last  months, or autologous stem cell transplant within the last  months before the date of study treatment administration.
Patients who have received prior allogeneic stem cell transplant
B-cell lymphoma patients who have received prior allogeneic stem cell transplant
Allogeneic stem cell transplant within  days before first dose of study drug
Autologous stem cell transplant following myeloablative therapy within  months prior to the first dose of abemaciclib or prior allogeneic stem cell transplant at any time; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria
Allogeneic stem cell transplant patients and any patient who has relapsed within  days of stem cell infusion following an autologous bone marrow transplant.
Patients must not have received allogeneic stem cell transplant
Stem cell transplant less than  months prior to enrolment.
Prior peripheral stem cell transplant within  weeks of the first dose of study treatment
Undergone an allogeneic stem cell transplant within the past  year
Prior allogeneic stem cell transplant.
Prior allogeneic stem cell transplant
Undergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)
Less than  days post-allogeneic stem cell transplant
Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures
Undergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)
Donors for allogeneic (i.e. human leukocyte antigen [HLA] matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures
Less than  days post-allogeneic stem cell transplant
Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ?  months prior to starting CC-.
Patients must have received an allogeneic stem cell transplant for a hematologic malignancy
Has received an allogeneic stem cell transplant
Prior peripheral stem cell transplant within  weeks of initiation of therapy
Allogeneic stem cell transplant within the past  year
One prior allogeneic stem cell transplant within the preceding  months.
Patients who have received prior allogeneic stem cell transplant will be permitted to enroll on the protocol
Prior allogeneic stem cell transplant is not permitted
Stem cell transplantation: Previously received an allogenic stem cell transplant; and/or received an autologous stem cell transplant less than or equal to (<=)  weeks before the first dose of study drug
Autologous hematologic stem cell transplant within  months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Relapsed or refractory disease after allogeneic transplant provided subject is at least  days from stem cell transplant at the time of enrollment
Prior stem cell transplant.
Received autologous stem cell transplant within  weeks before the date of randomization, or the participant has previously received allogeneic stem cell transplant (regardless of timing)
Allogeneic stem cell transplant within the last  months, or autologous stem cell transplant within the last  months before the date of first dose of study treatment.
Patients are eligible >  days after autologous stem cell infusion following myeloablative therapy; patients receiving an autologous stem cell infusion to support non-myeloablative therapy (including iodine [I]-MIBG given as a single agent) are eligible >=  weeks following the stem cell infusion provided they meet the hematologic and other organ function criteria for eligibility; patients who have received an allogeneic stem cell transplant are excluded
Prior allogeneic stem cell transplant
Prior stem cell transplant
Planned stem cell transplant during the first  cycles of protocol therapy are excluded. Stem cell collection during the first  cycles of protocol therapy is permitted
Prior allogeneic stem cell transplant is not permitted
Allogeneic hematologic stem cell transplant within  months of study entry
Must have received front-line chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous stem cell transplant or allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Eligible and willing to proceed with an allogeneic stem cell transplant with an acceptable stem cell donor
Prior allogeneic stem cell transplant
Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma
Patients with the diagnosis of severe AA, who are not currently candidates for an allogeneic stem cell transplant, fulfilling the following criteria:
Patients who have received a prior stem cell transplant
Patients had prior autologous or allogeneic stem cell transplant; prior stem cell collection is allowed
At least  weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion); patients who received stem cell infusion following non-myelo-ablative therapy are eligible once they meet all other eligibility requirements; patient must NOT have received a prior allogeneic hematopoietic stem cell transplant
Diagnosis of a hematological malignancy requiring an allogeneic stem cell transplant consistent with the standard of care
Patient with MDS who relapse after allogeneic stem cell transplant are eligible if they received standard dose decitabine or -azacytidine prior to or after stem cell transplant
Autologous hematologic stem cell transplant within  months of study entry or Allogeneic hematologic stem cell transplant within  months
RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant
A prior autologous transplant within  months of study entry or allogeneic stem cell transplant
Patients with the diagnosis of aplastic anemia who are either previously treated or untreated are eligible if they are not currently candidates for an allogeneic stem cell transplant
Patients that are eligible (including having available donor) and willing to receive an allogeneic stem cell transplant within  weeks
INCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT ):
EXCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT ):
One prior allogeneic stem cell transplant within the preceding  months
Has allogenic haemopoietic stem cell (HSC) transplant.
Prior allogeneic stem cell transplant.
Have undergone stem cell transplant (SCT), or are considered transplant ineligible.
Previously received allogeneic stem cell transplant and one or more of the following:
Patients who have received prior allogeneic stem cell transplant
Patients status post-allogeneic stem cell transplant are not eligible
Ineligible for allogeneic stem cell transplant
All patients with relapsed/refractory lymphoma must have received or be ineligible for autologous stem cell transplant or be ineligible for allogeneic stem cell transplant\r\n* NOTE: Patients must not have had a prior allogeneic stem cell transplant
Patients are not eligible who have had a prior allogeneic stem cell transplant\r\n* NOTE: Autologous stem cell transplant is acceptable
Stem Cell Transplant (SCT): \r\n* Patients are eligible  weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)\r\n* Patients are not eligible post allogeneic stem cell transplant\r\n* Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as  iodine [I]-MIBG) are eligible at any time as long as they meet the other criteria for eligibility
Prior stem cell transplant (autologous or allogeneic)
Patients that have received a prior autologous or allogeneic stem cell transplant
Prior autologous or allogeneic stem cell transplant
Prior allogeneic stem cell transplant
They have had an allogeneic stem cell transplant (received stem cell from someone else)
Patients status post allogeneic stem cell transplant.
Prior allogeneic stem cell or autologous transplant.
If a participant has received a transplant as his/her first-line therapy, he/she must be at least  months post transplantation and recovered from the side effects of the stem cell transplant.
Prior allogeneic or autologous stem cell transplant
Autologous hematologic stem cell transplant within  months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Patients may have had a prior autologous stem cell transplant; no prior history of allogeneic stem cell transplant
Prior peripheral stem cell transplant within  weeks of patient registration
Prior allogeneic stem cell transplant
Patients with diffuse large B cell lymphoma must have received at least two prior therapies and have received, declined or be ineligible for autologous or allogeneic stem cell transplant
Participants received an allogeneic stem cell transplant
Relapsed or refractory disease after allogeneic transplant provided subject is at least  days from stem cell transplant at the time of enrollment
Prior allogeneic stem cell transplant
Patients undergoing allogeneic stem cell transplant using a peripheral blood stem cell source
Autologous hematologic stem cell transplant within  months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
Autologous hematologic stem cell transplant within  months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded
Subject has undergone an allogeneic stem cell transplant within the past year
Have received an autologous or allogeneic stem-cell transplant
Has received autologous stem cell transplantation within  weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease
Prior allogeneic stem cell transplant
Prior allogeneic stem cell transplant (SCT), chest radiation ?  weeks from study drug, ? mg of Carmustine Bis-chloroethylnitrosourea (BCNU) as part of pre-transplant conditioning regimen, prior treatment with drug targeting T-cell costimulation or immune checkpoint pathways
No autologous or allogeneic stem cell transplant within  months prior to cycle  day 
Undergone an allogenic stem cell transplant
Autologous hematologic stem cell transplant within  months of study entry or Allogeneic hematologic stem cell transplant within  months;
Patient must not have undergone a prior allogeneic stem cell transplant
One prior allogeneic stem cell transplant within the preceding  months
Patients with prior autologous or allogeneic stem cell transplant are eligible as long as they meet all other criteria
Patients who have received a stem cell transplant in the past.
Patients who can receive an allogeneic stem cell transplant within  weeks.
Have previously received an allogenic stem cell transplant
Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
Prior allogeneic stem cell transplant
A prior allogeneic stem cell transplant
Both potentially autologous stem cell transplant (autoSCT) or allogeneic stem cell transplant (alloSCT) candidates and those who are not transplant candidates are eligible for the study
Have received an autologous or allogeneic stem-cell transplant within  days of the initial dose of study drug
A diagnosis of a hematologic malignancy for which stem cell transplant is standard of care
Not eligible for high-dose chemotherapy and stem cell transplant.
Underwent stem cell transplant < days prior to receiving first dose of ponatinib
Have received at least  prior treatment, which may include stem cell transplant.
Had allogeneic stem cell transplant within last  months and on immunosuppressive therapy.
Allogeneic stem cell transplant within the last  months, or autologous stem cell transplant within the last  months before the date of the first dose of study treatment.
Prior allogeneic stem cell transplant
Stem cell transplant within  days
Patients who are candidates for allogeneic stem cell transplant at the time of enrollment
Stem cell transplant within  months
Patients status post-allogeneic stem cell transplant are not eligible.
Candidates for allogeneic stem cell transplant at the time of screening.
For Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic hematopoietic stem cell transplant
For Pre-allo Part A (before stem cell transplant): Prior alloSCT
Received autologous stem cell transplant within  days or allogeneic transplant within  months prior to first dose of study drug
Prior stem cell transplant
Stem cell transplant within previous  months prior to initiation of study therapy
Current candidacy for a potentially curative allogeneic stem cell transplant, unless declined
Patients who are eligible, willing and able to receive an allogeneic stem cell transplant within  weeks are not eligible
Prior allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Patients < days since prior allogeneic stem cell transplant
ANC ? /?l (? /?l after stem cell transplant)
AML patients who are candidates for allogeneic stem cell transplant are excluded.
Patient with a prior stem cell transplant (both autologous and allogeneic)
Prior allogeneic stem cell transplant, except for a specific cohort
Patients who have received a prior allogeneic stem cell transplant are eligible if:
Subject has undergone an allogeneic stem cell transplant
Need for cytoreduction prior to allogeneic stem cell transplant.
Patient with diffuse large B cell lymphoma has received or is ineligible for autologous or allogeneic stem cell transplant.
Patients are not eligible post allogeneic stem cell transplant.
The patient is not considered to be an immediate candidate for allogeneic stem cell transplant as determined by the investigator.
Prior allogeneic stem cell transplant patients will be allowed to enroll if they are past day + of transplant, have no active graft-versus-host-disease, are not on any immunosuppressants and have been off immunosuppressants for at least  weeks; prior autologous stem cell transplant patients will also be allowed to enter this study if they are past their day + of transplant
Received an allogeneic stem cell transplant < months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participant
Prior peripheral stem cell transplant within  weeks of the first dose of study treatment
Prior allogeneic stem cell transplant.
Subjects who are planning for or who are eligible for stem cell transplant
Prior stem cell transplant
Prior allogeneic stem cell transplant more than  months from the first transplant, in remission
Prior peripheral stem-cell transplant within  weeks of the first dose of elotuzumab.
Patients who have had an allogeneic stem cell transplant are excluded
Appropriate third party payer coverage for \Homebound Stem Cell Transplant Program\
Planned stem cell transplant
Patient within  days of autologous/allogeneic (auto/allo) stem cell transplant and their stem cell physician does not approve yogurt ingestion
Planned allogeneic stem cell transplant with schedule that accommodates at least a  week exercise intervention, but not greater than  weeks
Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)
Pediatric patients admitted to the hospital for a stem cell transplant
ELIGIBILITY FOR CD SELECTED STEM CELL INFUSION FOLLOWING PRIOR ALLOGENEIC STEM CELL TRANSPLANT (MAY BE REFERRED TO AS A \BOOST\)
Prior allogeneic stem cell transplant
Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.
DONOR: Donors undergoing stem cell collection for match related allogeneic stem cell transplant
Subjects planning to undergo allogeneic stem cell transplant within  months of enrollment
Prior autologous or allogeneic stem cell transplant within defined period of initiation of therapy
Prior allogeneic stem cell transplant and/or chimeric antigen receptor T-cell therapy at any time.
Have received allogeneic stem cell transplant.
Stem cell transplant within the past  months